Navigation Links
Finnish researchers discovered a new anticancer compound
Date:5/21/2014

A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells. Their research also shows that new cancer drug candidates can be identified faster and at lower cost by using computer-assisted and cell-based screening of compounds.

The objective of the research project led by Marko Kallio, Principal Scientist at VTT, was to accelerate the drug development process by identifying new compounds that would possess similar binding properties and cellular phenotype , but a different chemical structure, as the selected drugs in clinical use or investigational compounds in development.

The scientists combined computer-based screening and cell-based assays to create a method that can significantly accelerate drug discovery and thereby lower development costs. It is highly likely that the new compounds identified using this method have not yet been patented.

The research team conducted a computer-assisted screening of 65,000 compounds and cell-based assays on the 150 highest scoring hit compounds, before identifying the Cent-1 molecule. The Cent-1 molecule kills cancer cells through a mechanism similar to that of the template drug Rigosertib that is currently under commercial development. However, since the chemical structure of the Cent-1 compound differs from Rigosertib, there are no major obstacles to further development.

What makes the study also significant is evidence that Rigosertib did not inhibit its reported target genes; there is reason to believe that the drug has a different mechanism of action at molecular level than anticipated. This drug discovery related study was published in the Molecular Cancer Therapeutics in April 2014.

Development of new drugs is an expensive and time-consuming process. It usually takes around 10󈝻 years to complete and costs several hundreds of millions of euros. In addition, risks associated with the usability, therapeutic efficacy and market share of medicinal substances are usually realised only in the final stages of drug development.


'/>"/>

Contact: Marko Kallio
marko.kallio@vtt.fi
358-207-222-810
VTT Technical Research Centre of Finland
Source:Eurekalert

Related medicine news :

1. Finnish team of researchers finds a mutation in a tumor of the jaw
2. Finnish research to revolutionise indications for knee surgery
3. Supermodel mouse reveals mechanisms that regulate metabolism, researchers find
4. Detroit Lions help rebuild city with innovative gridiron giving, U-M researchers say
5. Researchers examine intersection of aging, chronic disease
6. Researchers propose treating prison population to fight US hepatitis C epidemic
7. Researchers ID changes that may occur in neural circuits due to cocaine addiction
8. Researchers identify genetic marker linked to OCD
9. Mount Sinai researchers identify changes that may occur in neural circuits due to addiction
10. UTHealth CCTS Biobank continues to innovate allocation of resources for researchers
11. Three Nova Southeastern University researchers receive patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... ... 2017 , ... A recent report from the National Council on Teacher Quality ... report suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions ... U.S. It argues that this higher bar should be set by states, by the ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... ... 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers ... impact on the careers of all others involved. , On Monday, March 21st, ... MBI’s Hall of Fame. The induction took place during the World of Modular – ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
Breaking Medicine Technology: